ASCL1 and cancer: We successfully reprogrammed three glioblastoma cell lines, U251, U87, and KNS89, into a neural differentiation state by knocking down PTBP1. The reprogramming efficiency has reached more than 90%, which is a significant improvement over 20-40% of Ascl1, Brn2, and Ngn2 overexpression 47, suggesting that PTBP1 knockdown has met our criteria for modifying cancer progression.